Relationships between tumor microenvironment and clinicopathological parameters in meningioma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 10, 2014, Pages 6973-6979

  Ding, Yuanyuan ^a   Qiu, Lin ^a   Xu, Qian ^a   Song, Lixue ^a   Yang, Sufang ^b   Yang, Tao ^c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b 1st Ambulant Clinic Bureau Management and Security Military Upper Command   (China)

^c GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Cell subsets; Immunotherapies; Meningioma; Tumor microenvironment

Indexed keywords

CD20 ANTIGEN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; B LYMPHOCYTE; BIOPSY; CANCER GRADING; CD4+ T LYMPHOCYTE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MACROPHAGE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; B-LYMPHOCYTES; BIOPSY; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84912121685     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Backer-Grondahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol 2012; 5: 231-242.
2. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 1997; 21: 1455-1465.
3. Kerkar SP, Restifo NP. Cellular Constituents of Immune Escape within the Tumor Microenvironment. Cancer Res 2012; 72: 3125-3130.
4. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery 2005; 57: 1088-1095; discussion 1088-1095.
5. Pollock BE. Defining the best management for patients with intracranial WHO Grade II Meningiomas. World Neurosurg 2013; 81: 712-3.
6. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
7. Passacantilli E, Lapadula G, Caporlingua F, Lenzi J, Antonelli M, Santoro F, Santoro A. Chordoid meningioma: a retrospective series of seven consecutive cases. Neurol Sci 2013; 34: 1985-9.
8. Wu T, Yang Q, Li Z, Cai F, Zhu S, Zhang F. [Clinicopathological analysis of clear cell meningioma]. Nan Fang Yi Ke Da Xue Xue Bao 2012; 32: 131-134.
9. Sundaram C, Uppin SG, Uppin MS, Rekha JS, Panigrahi MK, Purohit AK, Rammurti S. A clinicopathological and immunohistochemical study of central nervous system hemangiopericytomas. J Clin Neurosci 2010; 17: 469-472.
10. Wu YT, Lin JW, Wang HC, Lee TC, Ho JT, Lin YJ. Clinicopathologic analysis of rhabdoid meningioma. J Clin Neurosci 2010; 17: 1271-1275.
11. van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM. The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 2003; 82: 539-548.
12. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011; 144: 646-674.
13. Yu P, Rowley DA, Fu YX, Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 2006; 18: 226-231.
14. Ladanyi A. [Prognostic value of tumor-infiltrating immune cells in melanoma]. Magy Onkol 2013; 57: 85-95.
15. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. Clin Cancer Res 2012; 18: 6758-6770.
16. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61: 5132-5136.
17. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Nati Acad Sci U S A 2005; 102: 18538-18543.
18. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Nati Acad Sci U S A 2007; 104: 3967-3972.
19. Liao Y, Ou J, Deng J, Geng P, Zeng R, Tian Y, Liang H, Ni B, Ruan Z. Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer. Med Oncol 2013; 30: 727.
20. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
21. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
22. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
23. Shevach EM. Fatal attraction: tumors beckon regulatory T cells. Nat Med 2004; 10: 900-901.
24. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, Zou W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67: 8900-8905.
25. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao DX, Gilks CB, Watson PH, Nelson BH. Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. PLoS One 2009; 4: e6412.
26. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168: 4272-4276.
27. Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, Shanyinde M, Lister TA, Calaminici M, Gribben JG. Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome. J Clin Oncol 2013; 31: 256-262.
28. Zou WP. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
29. Nielsen JS, Nelson BH. Tumor-infiltrating B cells and T cells Working together to promote patient survival. Oncoimmunology 2012; 1: 1623-1625.
30. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010; 185: 4977-4982.
31. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-237.
32. Qian BZ, Pollard JW. Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell 2010; 141: 39-51.
33. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117: 1155-1166.